Abstract
Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially ≥5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) ≥4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS ≥4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.
Original language | English (US) |
---|---|
Article number | mdp337 |
Pages (from-to) | 574-581 |
Number of pages | 8 |
Journal | Annals of Oncology |
Volume | 21 |
Issue number | 3 |
DOIs | |
State | Published - Sep 16 2009 |
Externally published | Yes |
Keywords
- Combined modality
- Hodgkin lymphoma
- Involved-field radiotherapy
- Stanford V
ASJC Scopus subject areas
- Hematology
- Oncology